Management and Prevention of Cardiovascular Disease in Metabolic Syndrome and Diabetes: Focus on PCSK9 Inhibitors
Thursday, December 1st, 2016
6:00 pm – 7:30 pm
Hilton Universal City, Los Angeles
A satellite symposium, to be held in association with the 14th World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease
Due to a high residual risk for CVD despite treatment with statins, there is a growing interest in having non-HDL cholesterol as the target of lipid management in the prevention and treatment of CVD. This symposium focuses on further reduction of LDL-cholesterol as well as other lipid components like Lp(a). Despite the availability of numerous clinical guidelines for the management of lipids to reduce CVD risk, appropriate application of these guidelines remains low, likely contributing to CVD morbidity and mortality. The overall objective of this CME program is to examine the prevalence of CVD in high-risk patients, discuss appropriate guidelines, provide an update on pharmacological strategies to reduce CVD risk, and offer expert insights into how to apply the lipid management guidelines and applicable treatment target goals to achieve better patient outcomes.
For More Information, please visit here.
Cost – $75 includes refreshments
To Register for the CME Symposium only, please click here.
To register for the entire 14th WCIRDC and CME Symposium
Please click here.